Last €9.85 EUR
Change Today -0.52 / -5.00%
Volume 760.0
GBY On Other Exchanges
Symbol
Exchange
GBY is not on other exchanges.
As of 9:48 AM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

sangamo biosciences inc (GBY) Snapshot

Open
€10.25
Previous Close
€10.37
Day High
€10.34
Day Low
€9.85
52 Week High
03/6/14 - €17.85
52 Week Low
06/24/13 - €5.25
Market Cap
656.9M
Average Volume 10 Days
2.2K
EPS TTM
--
Shares Outstanding
66.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SANGAMO BIOSCIENCES INC (GBY)

sangamo biosciences inc (GBY) Related Businessweek News

No Related Businessweek News Found

sangamo biosciences inc (GBY) Details

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins could be used to turn genes on or off. The company’s principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops CERE-110 that is in Phase II clinical trial for the treatment of Alzheimer’s disease. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, huntington’s disease, and hemoglobinopathies; and proprietary programs in the areas of lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including various immunodeficiencies, as well as central nervous system disorders and cancer immunotherapy. The company has collaboration and license agreements with Shire International GmbH and Biogen Idec Inc.; and strategic partnerships with Sigma-Aldrich Corporation, Dow AgroSciences, LLC, Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.

85 Employees
Last Reported Date: 02/24/14
Founded in 1995

sangamo biosciences inc (GBY) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $640.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $400.0K
Chief Medical Officer and Vice President of T...
Total Annual Compensation: $437.5K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $385.0K
Executive Vice President of Research and Deve...
Total Annual Compensation: $453.5K
Compensation as of Fiscal Year 2013.

sangamo biosciences inc (GBY) Key Developments

Sangamo Biosciences Inc. Approves Amendments to Certificate of Incorporation

The stockholders of Sangamo Biosciences Inc. approved an amendment to the company's Certificate of Incorporation to increase the company's authorized number of shares of common stock from 80,000,000 shares to 160,000,000 shares. The company's Board of Directors unanimously approved the Charter Amendment, subject to approval by the company's stockholders. The Charter Amendment became effective on April 22, 2014 upon filing of the Certificate of Amendment to the company's Certificate of Incorporation with the Secretary of State of Delaware.

Sangamo Biosciences Seeks Acquisitions

Sangamo Biosciences Inc. (NasdaqGS:SGMO) is looking for acquisitions. Sangamo BioSciences intends to raise $100 million through a public offering of shares of its common stock. Sangamo said it plans to use the proceeds from this offering for working capital and other general corporate purposes, including support for continuing research and development of ZFP Therapeutic product candidates and research programmess manufacturing capabilities for clinical and commercial production, clinical trials and business development activities and, if opportunities arise, acquisitions of businesses, products, technologies or licenses that are complementary to our business.

Sangamo BioSciences, Inc. Announces Publication of Clinical Study of Proprietary Zinc Finger Nuclease Based Genome Editing Technology in Humans

Sangamo BioSciences Inc. announced the publication in the New England Journal of Medicine of the first clinical study of its proprietary zinc finger nuclease (ZFN)-based genome editing technology in humans. Data from the study, carried out in HIV-positive subjects, demonstrate that the T-cell genome can be safely engineered to mimic a naturally occurring mutation that provides resistance to HIV infection. ZFN-modified T-cells are well tolerated when reinfused and treatment is associated with decreased viral loads (VLs) in several subjects who were taken off their antiretroviral therapy (ART) including one whose viral load became undetectable. The study demonstrates the feasibility of this novel genome editing approach to achieve functional control of HIV. Additional data on the ongoing SB-728-T ongoing clinical trials in HIV will be presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2014), which is taking place in Boston, March 3-6, 2014. In the study, T-cells from HIV subjects were isolated and edited with ZFNs to make them resistant to the virus by knocking out the CCR5 gene which encodes a coreceptor required for HIV infection. After modification, the cells (SB-728-T) were returned to the subject, in a so-called autologous infusion, and subjects were monitored for safety and a variety of immunological parameters. The modified cells readily engrafted and were able to traffic throughout the body to key sites of HIV persistence such as the gut-associated lymphoid tissue. The data demonstrate that the modified cells persist and moreover appear to have a selective advantage, showing a preferential survival compared to unmodified cells when exposed to HIV during a planned interruption of ART. SB-728-T treatment was associated with an increase in the levels of total circulating CD4 T-cells and was well tolerated. One of six subjects undergoing a treatment interruption experienced the longest delay in rebound of viral load when ART was withdrawn and achieved a decrease in VL to undetectable levels during the 12-week period. This subject was later found to carry a natural mutation of CCR5, CCR5 delta-32, in one of the two CCR5 genes (making the individual a CCR5 delta-32 heterozygote). Thus, following exposure to the ZFNs targeting CCR5, at baseline this subject to had a greater percentage of T-cells that were modified at both sites (biallelic modification) and were fully resistant to HIV infection. Preliminary analyses suggest that the levels of circulating cells with biallelic modification of CCR5 may correlate with control of viral load. The company has ongoing clinical studies in CCR5 delta-32 heterozygotes (SB-728-902, Cohort 5) and in subjects undergoing Cytoxan pre-conditioning (SB-728-1101) to further study this relationship. The study was an open-label, Phase 1 study of a single dose of approximately 10 billion ZFN-modified autologous T-cells in 12 HIV-infected subjects whose virus was well controlled by antiretroviral medications. Subjects were divided into two cohorts of six subjects each. Subjects in Cohort 1 were identified as immune responders who had demonstrated adequate recovery of CD4 T-cells after ART (>450 cells /mm(3)).Subjects in Cohort 2 were identified as individuals who had demonstrated inadequate recovery of CD4 T-cells after ART (200-500 cells /mm(3)), so-called immunologic non-responders. Four weeks after SB-728-T treatment, Cohort 1 subjects underwent an interruption from ART of up to 12 weeks. Cohort 2 remained on their ART throughout the study. The primary objective of the study was to assess safety and tolerability of administration of a single dose of SB-728-T. Secondary outcomes included measures of immune reconstitution and HIV resistance. The study was carried out at the Hospital of the University of Pennsylvania and the Jacobi Medical Center, Albert Einstein College of Medicine and was supported in part by an NIAID Program Project Grant.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GBY:GR €9.85 EUR -0.52

GBY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bluebird Bio Inc $19.95 USD -0.29
Fibrocell Science Inc $4.21 USD +0.17
View Industry Companies
 

Industry Analysis

GBY

Industry Average

Valuation GBY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.9x
Price/Book 7.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 34.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANGAMO BIOSCIENCES INC, please visit www.sangamo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.